Literature DB >> 23388112

Outcomes and care of patients with acute heart failure syndromes and cardiac troponin elevation.

Juarez R Braga1, Jack V Tu, Peter C Austin, Alice Chong, John J You, Michael E Farkouh, Heather J Ross, Douglas S Lee.   

Abstract

BACKGROUND: Cardiac troponins (cTn) may be elevated among patients with acute heart failure syndromes (AHFS). However, the optimal approach to management of AHFS with elevated cTn is unknown. METHODS AND
RESULTS: We compared the care and outcomes of 13 656 patients with AHFS seeking care in the emergency department stratified by presence (cTn+, n=1845, 13.5%) or absence (cTn-) of elevated troponin. Clinically abstracted data on patients who were admitted or discharged from the emergency department in Ontario, Canada (April 1999 to March 2001 and April 2004 to March 2007) were examined. In an exploratory 2:1 propensity-matched analysis, we examined whether early coronary revascularization (within 14 days of emergency department visit) was associated with survival, stratified by cTn status. For cTn+ AHFS, rates of coronary angiography (21.8 vs 11.4 patients/100 person-years; P<0.001) and coronary revascularization (8.8 vs 3.2 patients/100 person-years; P<0.001) were higher than cTn-. Instantaneous 30-day adjusted hazard ratios for cTn+ versus cTn- patients were 9.17 (95% confidence interval [CI], 8.31-10.12; P<0.001) for death, 5.14 (95% CI, 4.66-5.67; P<0.001) for cardiovascular readmission, and 13.08 (95% CI, 10.95-15.62; P<0.001) for ischemic heart disease hospitalization. In propensity-matched analysis of 143 individuals with cTn+ AHFS, early coronary revascularization was associated with reduced mortality (adjusted hazard ratio, 0.29; 95% CI, 0.09-0.92; P=0.036) compared with those who were not revascularized. Mortality was not significantly reduced among 210 cTn- patients undergoing early coronary revascularization (adjusted hazard ratio, 0.61; 95% CI, 0.36-1.03; P=0.065).
CONCLUSIONS: Elevated cTn was associated with increased risk of death and cardiovascular hospitalizations. Highly selected cTn+ patients who underwent early coronary revascularization for obstructive coronary artery disease experienced improved survival.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23388112     DOI: 10.1161/CIRCHEARTFAILURE.112.000075

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN: 1941-3289            Impact factor:   8.790


  15 in total

1.  Recurrent events analysis for examination of hospitalizations in heart failure: insights from the Enhanced Feedback for Effective Cardiac Treatment (EFFECT) trial.

Authors:  Juarez R Braga; Jack V Tu; Peter C Austin; Rinku Sutradhar; Heather J Ross; Douglas S Lee
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2018-01-01

2.  Frequency and Associations of Prescription Nonsteroidal Anti-inflammatory Drug Use Among Patients With a Musculoskeletal Disorder and Hypertension, Heart Failure, or Chronic Kidney Disease.

Authors:  Zachary Bouck; Graham C Mecredy; Noah M Ivers; Moumita Barua; Danielle Martin; Peter C Austin; Joshua Tepper; R Sacha Bhatia
Journal:  JAMA Intern Med       Date:  2018-11-01       Impact factor: 21.873

Review 3.  Cardiac troponin level elevations not related to acute coronary syndromes.

Authors:  Evangelos Giannitsis; Hugo A Katus
Journal:  Nat Rev Cardiol       Date:  2013-08-27       Impact factor: 32.419

4.  Using fractional polynomials and restricted cubic splines to model non-proportional hazards or time-varying covariate effects in the Cox regression model.

Authors:  Peter C Austin; Jiming Fang; Douglas S Lee
Journal:  Stat Med       Date:  2021-11-21       Impact factor: 2.497

5.  Association of heart-type fatty acid-binding protein with cardiovascular risk factors and all-cause mortality in the general population: the Takahata study.

Authors:  Yoichiro Otaki; Tetsu Watanabe; Hiroki Takahashi; Atushi Hirayama; Taro Narumi; Shinpei Kadowaki; Yuki Honda; Takanori Arimoto; Tetsuro Shishido; Takuya Miyamoto; Tsuneo Konta; Yoko Shibata; Akira Fukao; Makoto Daimon; Yoshiyuki Ueno; Takeo Kato; Takamasa Kayama; Isao Kubota
Journal:  PLoS One       Date:  2014-05-21       Impact factor: 3.240

6.  Persistent increase in cardiac troponin T at hospital discharge predicts repeat hospitalization in patients with acute decompensated heart failure.

Authors:  Seiji Takashio; Toshiyuki Nagai; Yasuo Sugano; Satoshi Honda; Atsushi Okada; Yasuhide Asaumi; Takeshi Aiba; Teruo Noguchi; Kengo F Kusano; Hisao Ogawa; Satoshi Yasuda; Toshihisa Anzai
Journal:  PLoS One       Date:  2017-04-05       Impact factor: 3.240

Review 7.  Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.

Authors:  Javier Díez
Journal:  Am J Cardiovasc Drugs       Date:  2014-08       Impact factor: 3.571

Review 8.  To Revascularise or Not To Revascularise, That Is the Question: the Diagnostic and Management Conundrum of Ischaemic Cardiomyopathy.

Authors:  Natalia Briceno; Divaka Perera
Journal:  Curr Cardiol Rep       Date:  2016-06       Impact factor: 2.931

Review 9.  Assessing Risk and Preventing 30-Day Readmissions in Decompensated Heart Failure: Opportunity to Intervene?

Authors:  Richard Dunbar-Yaffe; Audra Stitt; Joseph J Lee; Shanas Mohamed; Douglas S Lee
Journal:  Curr Heart Fail Rep       Date:  2015-10

10.  Comparison of Troponin Elevation, Prior Myocardial Infarction, and Chest Pain in Acute Ischemic Heart Failure.

Authors:  Cassandra Freitas; Xuesong Wang; Yin Ge; Heather J Ross; Peter C Austin; Peter S Pang; Dennis T Ko; Michael E Farkouh; Therese A Stukel; John J V McMurray; Douglas S Lee
Journal:  CJC Open       Date:  2020-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.